FundingPureTech Health gets US$11.4m to advance LYT-300Latest NewsLSE-listed PureTech Health plc hat been granted p to US$11.4m from U.S. Department of Defense to advance LYT-300 to treat Fragile X-associated tremor/ataxia syndrome. Read more 2 August 2023 https://european-biotechnology.com/wp-content/uploads/2024/04/US_Department_of_Defense.jpg 540 960 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2023-08-02 09:04:002024-07-09 15:08:08PureTech Health gets US$11.4m to advance LYT-300